Updated: Corporate Presentation
Piper Jaffray Conference Webcast KEYNOTE-695 SITC Poster
TAVO Demonstration SABCS Posters
BioCEO & Investor Conference Webcast
Learn more about our current clinical trials:
Advanced Melanoma Triple Negative Breast Cancer
Nature Gene Therapy: Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy
Immuno-Oncology News: TAVO reverses resistance to PD-1 inhibitors in metastatic melanoma, phase 2b trial suggests
Health Professionals Radio: President and CEO Dan O’Connor discusses late-stage studies in melanoma and TNBC.
Taking the fight directly to the tumor
Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.
Our core technology platform continues to advance through clinical trials for various cancers.
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.